Ani Pharmaceuticals (ANIP) Non-Current Assets (2010 - 2026)

Ani Pharmaceuticals has disclosed Non-Current Assets across 17 years of filings, most recently posting $668.7 million for Q2 2026.

• In Q2 2026, Non-Current Assets fell 9.68% year-over-year to $668.7 million; the TTM figure through Jun 2026 stood at $2.7 billion (down 9.21% YoY), while the FY2025 annual figure was $687.3 million, down 9.09% from the prior year.
• Non-Current Assets came in at $668.7 million for Q2 2026 at Ani Pharmaceuticals, down from $674.9 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $766.1 million in Q3 2024 to a low of $365.3 million in Q2 2024.
• Average Non-Current Assets over 5 years is $544.1 million, with a median of $436.6 million recorded in 2022.
• Year-over-year, Non-Current Assets surged 102.68% in 2025 and decreased 10.75% in 2026.
• Over 5 years, Non-Current Assets stood at $415.8 million in 2022, then dropped by 7.51% to $384.6 million in 2023, then soared by 96.57% to $756.0 million in 2024, then declined by 9.09% to $687.3 million in 2025, then fell by 2.7% to $668.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $668.7 million in Q2 2026, $674.9 million in Q1 2026, and $687.3 million in Q4 2025.